Dr. Mishra is Director of Bioinformatics and Co-Director of the Collaborative Genomics Center (CGC) at VGTI Florida®. He has expertise in Bioinformatics, Computational Biology, and Systems Biology and their applications for discovering and validating drug targets using large ‘Omics’ and other functional genomics datasets. His expertise spans across the entire value chain of translating research findings to valuable pre-clinical drug and diagnostic target molecules. He has a PhD degree in Molecular Biophysics from the State University of New York at Albany.
Dr. Mishra completed his post-doctoral training in the Life Sciences group at Los Alamos National Laboratory where he was instrumental in the design, development and implementation of the GenBank nucleotide sequence database. After completing his post-doctoral studies he joined the Genome Centre at Washington University, St. Louis, where he led the construction and publication of the first comprehensive linkage map of the human genome. In collaboration with several different Principal Investigators, he was very active in disease gene “hunting” and this resulted in the discovery of mutations in RET proto-oncogene that were responsible for the familial form of thyroid cancer.
Prior to joining VGTI Florida, Dr. Mishra, worked as a senior R&D leader in many Pharmaceutical companies. During the early part of his career, within the Pharmaceutical industry, he was focused on building world-class Bioinformatics groups, developing algorithms, tools, and creating infrastructures to enable and accelerate target and biologics discovery. During this time he pioneered and led the introduction of Genomics technologies and related information to supplement and enhance drug discovery methods within these companies. He was instrumental in the development of several informatics programs, tools, and platforms to provide high quality sequence, expression, and functional analysis and annotation of DNA, RNA, and protein molecules that accelerated and led to the discovery of novel drug targets, biological molecules, and diagnostics. These initiatives led to the identification of several molecules that subsequently entered pre-clinical studies with some advancing into clinical trials. Furthermore, he initiated, implemented, and played a key leadership and strategic role in the formation and development of “Lilly Systems Biology” organization in Singapore – he created a new business unit that comprised a group of multidisciplinary, multicultural scientists and staff to discover biomarkers for Cancer by creating and fostering a collegiate, team environment. In the later part, Dr. Mishra led Pharmaceutical R&D initiatives to discover and develop new chemical entities, differentiated formulations, bio-similar, generic small molecule drugs, and diagnostic kits. These initiatives led to the filing of New Drug Application (NDA) with the EMA (European Medicine Agency) and DCGI (Drug Controller General of India). One of these discovery products is currently in Phase II clinical development and was identified as one of the top five products in the world for potential treatment of metabolic disorder. Dr. Mishra served as a Special Advisor to the BioMedical Research Council (BMRC) of Singapore and was the Executive Director of the Bioinformatics Institute of Singapore. During this time, his research interests were in the areas of elucidation of protein functions, identification of microRNA and their targets, and developing Systems Biology applications to understand inflammation and innate immunity. Concurrently, he held a Professor position in the Department of Biochemistry, National University of Singapore where he taught and trained graduate students in Bioinformatics.
Dr. Mishra has over 40 publications in peer reviewed journals, and has presented numerous invited/plenary seminars at national, international, and thought leaders forums. His current research interests are in the areas of understanding the role of microRNA in biological and disease processes, in-depth understanding of the innate immune system, and applying these findings to develop precision molecular medicine that can benefit healthcare.